La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Genscript Biotech Dividendo

Dividendo criteri di controllo 0/6

Genscript Biotech al momento non paga dividendi.

Informazioni chiave

Rendimento del dividendo

Rapporto di remunerazione

Rendimento medio del settore	1.3%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	HK$0.012
Utile per azione	-HK$0.083
Previsione del rendimento del dividendo a 3 anni	0%

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar

Aug 02

Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch

Jun 05

A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)

May 10

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 13

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Mar 13

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 26

Is Genscript Biotech (HKG:1548) A Risky Investment?

Nov 21

Is Genscript Biotech (HKG:1548) A Risky Investment?

Aug 22

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Apr 04

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Apr 03

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 02

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Feb 07

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Dec 14

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 09

Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?

Mar 20

Are Insiders Selling Genscript Biotech Corporation (HKG:1548) Stock?

Feb 13

Did The Underlying Business Drive Genscript Biotech's (HKG:1548) Lovely 753% Share Price Gain?

Jan 09

Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?

Dec 05

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di 1548 siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di 1548 siano aumentati.

Rendimento dei dividendi rispetto al mercato

Genscript Biotech Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di 1548 rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (1548)	0%
Fondo del 25% del mercato (HK)	3.5%
Top 25% del mercato (HK)	8.4%
Media del settore (Life Sciences)	1.3%
Previsione dell'analista in 3 anni (1548)	0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di 1548 rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di 1548 rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: 1548 non sta pagando un dividendo degno di nota per il mercato Hong Kong.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché 1548 non ha segnalato alcun pagamento.

Genscript Biotech Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

Consensus EPS estimates fall by 46%

First half 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar

Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)

Full year 2023 earnings: EPS exceeds analyst expectations

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Consensus estimates of losses per share improve by 12%

Consensus EPS estimates upgraded to US$0.054 loss, revenue downgraded

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

New minor risk - Profitability

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Executive Chairman recently sold HK$610k worth of stock

Executive Chairman exercised options and sold HK$4.5m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Independent Non-Executive Director exercised options and sold HK$1.6m worth of stock

Non-Executive Director exercised options and sold HK$2.4m worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

Is Genscript Biotech (HKG:1548) A Risky Investment?

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Consensus revenue estimates fall by 19%

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Is Genscript Biotech (HKG:1548) A Risky Investment?

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Less than half of directors are independent

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Is Genscript Biotech (HKG:1548) Using Debt Sensibly?

Consensus forecasts updated

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Co-Founder exercised options and sold HK$327k worth of stock

Genscript Biotech Corporation Announces Board Changes

Less than half of directors are independent

Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Consensus forecasts updated

Key Executive exercised options and sold HK$897k worth of stock

Board Member exercised options and sold HK$1.1m worth of stock

Board Member recently sold HK$2.1m worth of stock

Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?

Co-Founder exercised options and sold HK$93m worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Estimating The Fair Value Of Genscript Biotech Corporation (HKG:1548)

Key Executive recently sold HK$9.1m worth of stock

Co-Founder exercised options and sold HK$165m worth of stock

Co-Founder exercised options and sold HK$72m worth of stock

Co-Founder exercised options and sold HK$74m worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test